SBLOF (Shin Nippon Biomedical Laboratories) Moat Score: 4/10 (As of Jun. 29, 2026)


SBLOF Shin Nippon Biomedical Laboratories Ltd SBLOF
77 GF Score
Price $9.16
GF Value $14.46
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories Moat Score?

Shin Nippon Biomedical Laboratories SBLOF -2.13% 77 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates SBLOF with a GF Score™ of 77/100 and a GF Value™ of $14.46. The stock has 5 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Shin Nippon Biomedical Laboratories ranks better than 82.87% on this metric.

Shin Nippon Biomedical Laboratories has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Shin Nippon Biomedical Laboratories has Narrow Moat: Shin Nippon Biomedical has a modest moat due to its specialized research capabilities and some proprietary technology. However, it faces competition from larger firms with more extensive R&D budgets, limiting its market leadership and pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Shin Nippon Biomedical Laboratories might have Narrow Moat - Discernible but modest moat.

Shin Nippon Biomedical Laboratories  (OTCPK:SBLOF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Shin Nippon Biomedical Laboratories Moat Score Related Terms

SBLOF vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shin Nippon Biomedical Laboratories Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Moat Score distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Moat Score falls into.


SBLOF
77GF Score
Shin Nippon Biomedical Laboratories Ltd SBLOF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #37 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 17.1%.
Is Shin Nippon Biomedical Laboratories' Moat Score too high?
Shin Nippon Biomedical Laboratories' current Moat Score is 4. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #37 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #37 out of 216 companies for Moat Score. This places Shin Nippon Biomedical Laboratories in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Shin Nippon Biomedical Laboratories's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Moat Score of 4. The stock's GF Value™ is $14.46, compared to a current price of $9.16 — trading 36.6% below its estimated fair value. The current Moat Score is 4. Shin Nippon Biomedical Laboratories' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of $9.16 is trading 36.6% below its estimated GF Value™ of $14.46.

Key valuation signals for SBLOF:

  • Moat Score: 4
  • GF Value™: $14.46 vs. price of $9.16 (36.6% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
77GF Score

Get the complete analysis for SBLOF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.16
Price
$14.46
GF Value